Ajanta Pharma Limited — Important, 18-06-2025: Updates

Ajanta Pharma has announced a board meeting on 17 July 2025 to approve the financial results for the quarter and half-year. The company reported 10% revenue growth to ₹4,648 Cr with a 7% increase in EBITDA to ₹1,260 Cr (27% margin) and 13% rise in PAT to ₹920 Cr (20% margin). Branded Generics contributed a historic 74% of revenue, growing 15%, driven by chronic therapies expansion and increased field force. India sales up 11% to ₹1,452 Cr, outperforming the market. US Generics grew 9%, with new launches set to boost FY26. Africa Institutional business declined 41%, now just 3% of revenue. Capex stood at ₹318 Cr including new liquid manufacturing facility and office. The company distributed ₹700 Cr to shareholders via dividend and buyback. ROCE improved to 32%. Sustainability efforts expanded solar capacity to 12.6 MW, cutting 14,000 tons of CO2. No new management or regulatory issues reported; Secretarial Auditor appointment and MD re-appointment are on agenda.